Protocol Ledger

NCT04729608 · Phase III · TERMINATED

Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Interventional Phase III clinical trial protocol NCT04729608 sponsored by Aravive in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-04-22 Enrollment: 366 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04729608
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)366 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04729608
Protocol FieldVerified Registry Value
NCT IdentifierNCT04729608
Consolidated Lead SponsorAravive
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment366 participants (ACTUAL)
Registered Start Date2021-04-22
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI